Press Releases
Announcements issued by Philogen, each linking its official release.
Philogen S.p.A announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma
Philogen S.p.A announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an…
Philogen S.p.A. announced that Pfizer Inc. (NYSE: PFE) has exercised options granted under the agreement established in December 2014
Philogen S.p.A. announced that Pfizer Inc. (NYSE: PFE) has exercised options granted under the agreement established in December 2014 for the potential…
Philogen is awarded a research grant from “Regione Toscana”
Philogen is awarded a research grant from “Regione Toscana” for a project focusing on the development of new strategies of Factor V purification for patients in…
Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim
Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute…
Dario Neri and his lab at the ETH Zurich are the recipient of an ERC Advanced Grant
Dario Neri and his lab at the ETH Zurich are the recipient of an ERC Advanced Grant for the project titled “Zauberkugel: fulfilling Paul Ehrlich’s dream of…
Philochem announced the publication in the prestigious journal Nature Chemistry
Philochem announced the publication in the prestigious journal Nature Chemistry of an article entitled ‘Dual-display of small molecules enables the discovery of…
Philogen announced Option and License Agreement with Pfizer Inc.
Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nano particles…
Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference
Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference. Huntingdon…